Related Experiment Video
Updated: Sep 20, 2025
05:16
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
6.9K
Do NGS-based techniques represent a first-line testing in suspected Duchenne muscular dystrophy?
Seyed Mohammad Hosseini1, Nosratollah Alizadeh2, Abolfazl Amini3
1Laboratory Sciences Research Center Golestan University of Medical Sciences Gorgan Iran.
Clinical Case Reports
|June 6, 2022
Summary
Duchenne muscular dystrophy (DMD) is diagnosed using Next-Generation Sequencing (NGS). This cost-effective molecular diagnostic strategy efficiently identifies patients with DMD, a genetic muscle-weakening disease.
Area of Science:
- Genetics
- Molecular Biology
- Pediatrics
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder.
- It results from mutations in the dystrophin gene, primarily affecting males.
- Muscle weakness is a hallmark symptom.
Observation:
- An 8-year-old child presented with classic symptoms of muscle weakness.
- This case highlights the clinical presentation of DMD.
Findings:
- Next-Generation Sequencing (NGS) is a viable diagnostic tool for DMD.
- NGS offers an efficient and cost-effective molecular diagnostic strategy.
Implications:
- Early and accurate diagnosis of DMD is crucial for patient management.
- NGS can improve the identification of individuals with DMD.
- This approach supports timely intervention and genetic counseling.
